Mechanism of hepatobiliary toxicity of the LPA(1) antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278

Gill, MW; Murphy, BJ; Cheng, PTW; Sivaraman, L; Davis, M; Lehman-McKeeman, L

Gill, MW (通讯作者)，104n Temperance Lane, Richboro, PA 18945 USA.

TOXICOLOGY AND APPLIED PHARMACOLOGY, 2022; 438 ():

Abstract

In a Phase 2 clinical trial, BMS-986020, a lysophosphatidic acid receptor-1 (LPA 1 ) antagonist, produced hepatobiliary toxicity (increased ALT, AST, ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索